Browse

Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial

Cited 197 time in Web of Science Cited 234 time in Scopus
Authors
Kang, Hyun-Jae; Lee, Hae-Young; Na, Sang-Hoon; Chang, Sung-A; Park, Kyung-Woo; Kim, Hyung-Kwan; Kim, Song-Yi; Chang, Ho-Joon; Lee, Whal; Kang, Won Jun; Koo, Bon-Kwon; Kim, Yong-Jin; Lee, Dong Soo; Sohn, Dae-Won; Han, Kyou-Sup; Oh, Byung-Hee; Park, Young-Bae; Kim, Hyo-Soo
Issue Date
2006-07-06
Publisher
American Heart Association
Citation
Circulation. 2006 Jul 4;114(1 Suppl):I145-51.
Keywords
Acute DiseaseAgedAngioplasty, Transluminal, Percutaneous CoronaryCoronary Restenosis/*prevention & controlCoronary VesselsDrug ImplantsEchocardiography, Doppler, ColorFemaleGranulocyte Colony-Stimulating Factor/pharmacologyHematopoietic Stem Cell MobilizationHumansHyperplasiaInjections, Intra-ArterialMagnetic Resonance ImagingMagnetic Resonance Imaging, CineMaleMiddle AgedMyocardial Infarction/pathology/*surgeryPeripheral Blood Stem Cell Transplantation/*methodsStentsStroke VolumeTransplantation, AutologousTreatment OutcomeTunica Intima/pathology*Ventricular Function, Left*Ventricular Remodeling
Abstract
BACKGROUND: The efficacy of intracoronary infusion of granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSCs) has not been compared between patients with acute (AMI) versus old myocardial infarction (OMI). In addition, the potential risk of restenosis associated with G-CSF-based stem cell therapy has not been evaluated in the setting of drug eluting stent (DES) implantation. METHODS AND RESULTS: We randomly allocated 96 patients with myocardial infarction who underwent coronary revascularization with DES for the culprit lesion into 4 groups. Eighty-two patients completed 6-month follow-up; AMI cell infusion (n=25), AMI control (n=25), OMI cell infusion (n=16), and OMI control group (n=16). In cell infusion groups, PBSCs were mobilized by G-CSF for 3 days and delivered to infarcted myocardium via intracoronary infusion. The AMI cell infusion group showed a significant additive improvement in left ventricular ejection fraction (LVEF) and remodeling compared with controls (change of LVEF: +5.1+/-9.1% versus -0.2+/-8.6%, P<0.05; change of end-systolic volume: -5.4+/-17.0 mL versus 6.5+/-21.9 mL, P<0.05). In OMI patients, however, there was no significant change of LVEF and ventricular remodeling in spite of significant improvement of coronary flow reserve after cell infusion. G-CSF-based cell therapy did not aggravate neointimal growth with DES implantation. CONCLUSIONS: Intracoronary infusion of mobilized PBSCs with G-CSF improves LVEF and remodeling in patients with AMI but is less definite in patients with OMI. G-CSF-based stem cell therapy with DES implantation is both feasible and safe, eliminating any potential for restenosis.
ISSN
1524-4539 (Electronic)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16820564

http://hdl.handle.net/10371/38231
DOI
https://doi.org/10.1161/CIRCULATIONAHA.105.001107
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Molecular and Genomic Medicine (분자유전체의학전공)Journal Papers (저널논문_분자유전체의학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse